U.S. Markets close in 3 hrs 45 mins
  • S&P 500

    4,534.89
    -1.30 (-0.03%)
     
  • Dow 30

    35,490.82
    -118.52 (-0.33%)
     
  • Nasdaq

    15,165.44
    +43.76 (+0.29%)
     
  • Russell 2000

    2,287.53
    -2.24 (-0.10%)
     
  • Gold

    1,783.50
    -1.40 (-0.08%)
     
  • EUR/USD

    1.1641
    -0.0011 (-0.0931%)
     
  • 10-Yr Bond

    1.6630
    +0.0270 (+1.65%)
     
  • Vix

    15.42
    -0.07 (-0.45%)
     
  • GBP/USD

    1.3805
    -0.0021 (-0.1491%)
     
  • USD/JPY

    113.7800
    -0.5490 (-0.4802%)
     
  • BTC-USD

    63,273.86
    -3,478.43 (-5.21%)
     
  • CMC Crypto 200

    1,498.09
    -36.55 (-2.38%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Reata Pharmaceuticals, Inc. RETA shares soared 5.3% in the last trading session to close at $149.95. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.5% gain over the past four weeks.

The company's share price has been rising since the FDA has asked the company to request a pre-NDA meeting to discuss study data for omaveloxolone, last month. The suggestion of a pre-NDA meeting has boosted investor sentiments for a potential new drug application filling, seeking approval for omaveloxolone much sooner than previously anticipated. The positive sentiments are likely to continue.

This company is expected to post quarterly loss of $2.13 per share in its upcoming report, which represents a year-over-year change of -4.9%. Revenues are expected to be $1.45 million, down 52.9% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Reata Pharmaceuticals, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RETA going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Reata Pharmaceuticals, Inc. (RETA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.